Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
March 4, 2019
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM,